You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 18, 2025

CLINICAL TRIALS PROFILE FOR SYMLIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Symlin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00189514 ↗ A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects Completed AstraZeneca Phase 2 2005-09-01 This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
NCT00229658 ↗ An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Completed AstraZeneca 2005-09-01 This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.
NCT00240253 ↗ A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes Completed AstraZeneca Phase 4 2005-10-01 The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.
NCT00313183 ↗ A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus Completed AstraZeneca Phase 2 2006-04-01 This study will be the first evaluation of Symlin in adolescent subjects with type 1 diabetes mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and physiological effects (pharmacodynamics), and safety and tolerability of Symlin in these subjects.
NCT00402077 ↗ A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects Completed AstraZeneca Phase 2 2006-11-01 This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Symlin

Condition Name

Condition Name for Symlin
Intervention Trials
Type 2 Diabetes Mellitus 4
Type 1 Diabetes 4
Obesity 3
Type 1 Diabetes Mellitus 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Symlin
Intervention Trials
Diabetes Mellitus 11
Diabetes Mellitus, Type 1 8
Diabetes Mellitus, Type 2 6
Body Weight 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Symlin

Trials by Country

Trials by Country for Symlin
Location Trials
United States 152
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Symlin
Location Trials
New York 9
Texas 8
Florida 7
Colorado 7
Pennsylvania 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Symlin

Clinical Trial Phase

Clinical Trial Phase for Symlin
Clinical Trial Phase Trials
Phase 4 8
Phase 3 1
Phase 2 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Symlin
Clinical Trial Phase Trials
Completed 13
Withdrawn 3
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Symlin

Sponsor Name

Sponsor Name for Symlin
Sponsor Trials
AstraZeneca 7
Amylin Pharmaceuticals, LLC. 5
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Symlin
Sponsor Trials
Other 16
Industry 14
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

SYMLIN (Pramlintide): Clinical Trials, Market Analysis, and Projections

Introduction to SYMLIN

SYMLIN, or pramlintide acetate, is a synthetic analog of human amylin, a hormone naturally produced by the pancreas. It is used to help control blood sugar levels in patients with type 1 and type 2 diabetes who are already using insulin. Here, we will delve into the clinical trials, market analysis, and future projections for SYMLIN.

Clinical Trials Overview

Early Phase III Trials and FDA Interactions

In the late 1990s, Amylin Pharmaceuticals conducted several Phase III clinical trials for SYMLIN. These trials faced initial setbacks, including disappointing results in some dose groups and concerns over study design and safety data. However, after modifying the test protocols, including using a constant dose of insulin and more stringent selection of study participants, the trials showed more promising results[3].

Meta-Analysis on Cardiovascular Safety

A significant meta-analysis presented at the 70th Annual Scientific Sessions of the American Diabetes Association in 2010 showed no increased risk of cardiovascular adverse events associated with SYMLIN treatment in patients with type 2 diabetes. This analysis included five randomized, controlled clinical trials and found that the relative risk for primary major adverse cardiovascular events (MACE) was 0.86, with a 95% confidence interval of 0.55–1.34, well below the FDA-specified threshold of 1.8[1].

Ongoing and Future Trials

A recent clinical trial, identified as study 137-162, is the first to evaluate SYMLIN in adolescent subjects with type 1 diabetes mellitus. This randomized, single-blind, dose-rising, placebo-controlled, crossover study aims to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of SYMLIN in this population[4].

Market Analysis

Current Market Status

The global market for SYMLIN is dominated by AstraZeneca, which acquired the rights to the drug after Amylin Pharmaceuticals was acquired. The market is segmented by type (1.5ml pen-injector and 2.7ml pen-injector) and by application (type 1 and type 2 diabetes)[5].

Revenue and Growth Projections

The global SYMLIN market is expected to grow significantly over the next few years. According to market research reports, the revenue from SYMLIN is projected to increase from its current value in 2023 to a substantial figure by 2030, with a compound annual growth rate (CAGR) that reflects the growing demand for effective diabetes management solutions[5].

Regional Analysis

The market for SYMLIN is expected to be strong in regions with high prevalence of diabetes, particularly in the United States and other developed countries. However, emerging markets are also anticipated to contribute significantly to the growth due to increasing awareness and better healthcare infrastructure[2].

Market Drivers and Restraints

Drivers

  • Increasing Prevalence of Diabetes: The rising global incidence of type 1 and type 2 diabetes drives the demand for effective glucose control medications like SYMLIN.
  • Advancements in Healthcare: Improvements in healthcare infrastructure and increased access to diabetes treatments in emerging markets are key drivers.
  • Regulatory Approvals: Positive outcomes from clinical trials and regulatory approvals enhance market confidence and adoption[2].

Restraints

  • Competition: The diabetes management market is highly competitive, with numerous other medications and treatments available.
  • Safety Concerns: Historical concerns over severe hypoglycemia and other adverse events, although largely mitigated by recent studies, can still impact market perception[3].
  • Economic Factors: Pricing and reimbursement issues can affect market acceptance and growth[1].

Technological and Competitive Landscape

Technological Trends

The development of new delivery systems and formulations is a key technological trend in the SYMLIN market. For instance, the availability of pen-injectors has made administration more convenient and user-friendly[5].

Competitive Analysis

AstraZeneca is the primary player in the SYMLIN market, but other pharmaceutical companies are also developing similar amylin mimetics. The competitive landscape is characterized by ongoing research and development to improve efficacy and safety profiles of these drugs[2].

Consumer Behavior and ESG Analysis

Consumer Behavior

Patients with diabetes are increasingly seeking medications that offer better glucose control with minimal side effects. The convenience of SYMLIN, administered at mealtime, aligns with these preferences. Additionally, patient education programs and support from healthcare providers play a crucial role in adoption[2].

ESG Analysis

Environmental, Social, and Governance (ESG) factors are becoming more important in the pharmaceutical industry. Companies like AstraZeneca are focusing on sustainable practices, ethical business conduct, and social responsibility, which can positively impact market perception and investor confidence[2].

Future Projections and Key Takeaways

Market Growth

The SYMLIN market is poised for significant growth driven by increasing demand for effective diabetes management solutions. The CAGR is expected to be substantial, reflecting the expanding global market and improving healthcare infrastructure.

Clinical Trials

Ongoing and future clinical trials, such as the study in adolescent subjects with type 1 diabetes, will continue to provide valuable data on the safety and efficacy of SYMLIN, potentially expanding its use to new patient populations.

Regulatory and Safety Profile

The robust safety profile of SYMLIN, particularly regarding cardiovascular risks, has been established through comprehensive meta-analyses. This will continue to support regulatory approvals and market confidence.

"People with diabetes are two to four times more likely to develop cardiovascular disease because of increased risk factors such as high blood pressure, lipid disorders and obesity," said Orville G. Kolterman, M.D., senior vice president, chief medical officer at Amylin[1].

Key Takeaways

  • Clinical Safety: SYMLIN has been shown to have a favorable cardiovascular safety profile in patients with type 2 diabetes.
  • Market Growth: The global SYMLIN market is expected to grow significantly, driven by increasing diabetes prevalence and advancements in healthcare.
  • Technological Advancements: New delivery systems and ongoing clinical trials are expected to enhance the efficacy and convenience of SYMLIN.
  • Competitive Landscape: AstraZeneca dominates the market, but competition from other amylin mimetics is anticipated.
  • Consumer Preferences: Patients seek medications with better glucose control and minimal side effects, aligning with SYMLIN's benefits.

FAQs

What is SYMLIN used for?

SYMLIN (pramlintide acetate) is used to help control blood sugar levels in patients with type 1 and type 2 diabetes who are already using insulin.

What are the key findings from the meta-analysis on SYMLIN's cardiovascular safety?

The meta-analysis showed no increased risk of cardiovascular adverse events associated with SYMLIN treatment in patients with type 2 diabetes, with a relative risk of 0.86 and a 95% confidence interval of 0.55–1.34[1].

Which company is the main player in the SYMLIN market?

AstraZeneca is the primary player in the SYMLIN market, having acquired the rights to the drug after Amylin Pharmaceuticals was acquired[5].

What are the main drivers of the SYMLIN market?

The main drivers include the increasing prevalence of diabetes, advancements in healthcare infrastructure, and positive regulatory approvals[2].

Are there ongoing clinical trials for SYMLIN?

Yes, there are ongoing clinical trials, including a study evaluating SYMLIN in adolescent subjects with type 1 diabetes mellitus[4].

Sources

  1. PR Newswire: "Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated with SYMLIN Treatment in Patients with Type 2 Diabetes"[1].
  2. Cognitive Market Research: "Symlin pramlintide Market Report 2024 (Global Edition)"[2].
  3. Casetext: "Amylin Pharmaceuticals, Inc. Securities Litigation"[3].
  4. AstraZeneca Clinical Trials: "A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus"[4].
  5. Valuates Reports: "Global Symlin (pramlintide) Market Research Report 2024"[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.